ALZAMEND NEURO, INC. Increase (Decrease) in Prepaid Expense and Other Assets
ALZAMEND NEURO, INC. (ALZN) reported Increase (Decrease) in Prepaid Expense and Other Assets of -$390.37 thousand for the 3-month period ending 2026-07-31, per its 10-Q filed 2026-09-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-09-10
- ALZAMEND NEURO, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-07-31 was -$390.37K, a 592.65% decline year-over-year.
- ALZAMEND NEURO, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-04-30 was $67.67K.
- ALZAMEND NEURO, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-01-31 was $714.13K.
- ALZAMEND NEURO, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-10-31 was -$35.94K, a 107.96% decline year-over-year.
- ALZAMEND NEURO, INC. increase (decrease) in prepaid expense and other assets for fiscal 2026 was $825.09K, a 451.81% increase from fiscal 2025.
- ALZAMEND NEURO, INC. increase (decrease) in prepaid expense and other assets for fiscal 2025 was $149.53K.
- ALZAMEND NEURO, INC. increase (decrease) in prepaid expense and other assets for fiscal 2024 was -$368.39K, a 476.43% decline from fiscal 2023.
- ALZAMEND NEURO, INC. increase (decrease) in prepaid expense and other assets for fiscal 2023 was $97.87K.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-07-31 | -$390.37K 10-Q · filed 2026-09-10 | -$322.71K derived: sum of 2 quarters · filed 2026-09-10 | $391.42K derived: sum of 3 quarters · filed 2026-09-10 | $355.48K derived: sum of 4 quarters · filed 2026-09-10 |
| 2026-04-30 | $67.67K derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-22 | $781.79K derived: sum of 2 quarters · filed 2026-07-22 | $745.85K derived: sum of 3 quarters · filed 2026-07-22 | $825.09K 10-K · filed 2026-07-22 |
| 2026-01-31 | $714.13K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-03-11 | $678.18K derived: sum of 2 quarters · filed 2026-03-11 | $757.42K 10-Q · filed 2026-03-11 | $396.94K derived: sum of 4 quarters · filed 2026-09-10 |
| 2025-10-31 | -$35.94K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-12-09 | $43.30K 10-Q · filed 2025-12-09 | -$317.19K derived: sum of 3 quarters · filed 2026-09-10 | -$401.65K derived: sum of 4 quarters · filed 2026-09-10 |
| 2025-07-31 | $79.24K 10-Q · filed 2026-09-10 | -$281.25K derived: sum of 2 quarters · filed 2026-09-10 | -$365.71K derived: sum of 3 quarters · filed 2026-09-10 | $85.72K derived: sum of 4 quarters · filed 2026-09-10 |
| 2025-04-30 | -$360.49K derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-22 | -$444.95K derived: sum of 2 quarters · filed 2026-07-22 | $6.48K derived: sum of 3 quarters · filed 2026-07-22 | $149.53K 10-K · filed 2026-07-22 |
| 2025-01-31 | -$84.46K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-03-11 | $366.97K derived: sum of 2 quarters · filed 2026-03-11 | $510.01K 10-Q · filed 2026-03-11 | $278.47K derived: sum of 4 quarters · filed 2026-03-11 |
| 2024-10-31 | $451.43K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-12-09 | $594.48K 10-Q · filed 2025-12-09 | $362.93K derived: sum of 3 quarters · filed 2025-12-09 | $91.87K derived: sum of 4 quarters · filed 2025-12-09 |
| 2024-07-31 | $143.05K 10-Q · filed 2025-09-10 | -$88.50K derived: sum of 2 quarters · filed 2025-09-10 | -$359.56K derived: sum of 3 quarters · filed 2025-09-10 | -$495.95K derived: sum of 4 quarters · filed 2025-09-10 |
| 2024-04-30 | -$231.54K derived: 10-K 12 month − 10-Q 9 month · filed 2025-07-22 | -$502.61K derived: sum of 2 quarters · filed 2025-07-22 | -$638.99K derived: sum of 3 quarters · filed 2025-07-22 | -$368.39K 10-K · filed 2025-07-22 |
| 2024-01-31 | -$271.06K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-03-10 | -$407.45K derived: sum of 2 quarters · filed 2025-03-10 | -$136.85K 10-Q · filed 2025-03-10 | -$235.56K derived: sum of 4 quarters · filed 2025-03-10 |
| 2023-10-31 | -$136.39K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-12-11 | $134.21K 10-Q · filed 2024-12-11 | $35.50K derived: sum of 3 quarters · filed 2024-12-11 | $172.23K derived: sum of 4 quarters · filed 2024-12-11 |
| 2023-07-31 | $270.60K 10-Q · filed 2024-09-11 | $171.88K derived: sum of 2 quarters · filed 2024-09-11 | $308.61K derived: sum of 3 quarters · filed 2024-09-11 | $130.65K derived: sum of 4 quarters · filed 2024-09-11 |
| 2023-04-30 | -$98.71K derived: 10-K 12 month − 10-Q 9 month · filed 2024-07-30 | $38.02K derived: sum of 2 quarters · filed 2024-07-30 | -$139.95K derived: sum of 3 quarters · filed 2024-07-30 | $97.87K 10-K · filed 2024-07-30 |
| 2023-01-31 | $136.73K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-03-25 | -$41.24K derived: sum of 2 quarters · filed 2024-03-25 | $196.58K 10-Q · filed 2024-03-25 | -$92.52K derived: sum of 4 quarters · filed 2024-03-25 |
| 2022-10-31 | -$177.97K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-12-15 | $59.85K 10-Q · filed 2023-12-15 | -$229.25K derived: sum of 3 quarters · filed 2023-12-15 | -$518.63K derived: sum of 4 quarters · filed 2023-12-15 |
| 2022-07-31 | $237.82K 10-Q · filed 2023-09-13 | -$51.28K derived: sum of 2 quarters · filed 2023-09-13 | -$340.66K derived: sum of 3 quarters · filed 2023-09-13 | -$611.95K derived: sum of 4 quarters · filed 2023-09-13 |
| 2022-04-30 | -$289.10K derived: 10-K 12 month − 10-Q 9 month · filed 2023-07-27 | -$578.48K derived: sum of 2 quarters · filed 2023-07-27 | -$849.77K derived: sum of 3 quarters · filed 2023-07-27 | -$633.60K 10-K · filed 2023-07-27 |
| 2022-01-31 | -$289.38K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-03-15 | -$560.66K derived: sum of 2 quarters · filed 2023-03-15 | -$344.49K 10-Q · filed 2023-03-15 | -$5.00 derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-10-31 | -$271.29K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-12-12 | -$55.12K 10-Q · filed 2022-12-12 | $289.37K derived: sum of 3 quarters · filed 2022-12-12 | $160.00K derived: sum of 4 quarters · filed 2022-12-12 |
| 2021-07-31 | $216.17K 10-Q · filed 2022-09-13 | $560.66K derived: sum of 2 quarters · filed 2022-09-13 | $431.28K derived: sum of 3 quarters · filed 2022-09-13 | $301.91K derived: sum of 4 quarters · filed 2022-09-13 |
| 2021-04-30 | $344.49K derived: 10-K 12 month − 10-Q 9 month · filed 2022-07-19 | $215.11K derived: sum of 2 quarters · filed 2022-07-19 | $85.74K derived: sum of 3 quarters · filed 2022-07-19 | -$260.79K 10-K · filed 2022-07-19 |
| 2021-01-31 | -$129.38K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-03-15 | -$258.75K derived: sum of 2 quarters · filed 2022-03-15 | -$605.28K 10-Q · filed 2022-03-15 | |
| 2020-10-31 | -$129.38K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-12-13 | -$475.90K 10-Q · filed 2021-12-13 | ||
| 2020-07-31 | -$346.53K 10-Q · filed 2021-09-13 | |||
| 2020-04-30 | $15.76K 10-K · filed 2021-07-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B |